These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Villaseca P Climacteric; 2012 Apr; 15(2):115-24. PubMed ID: 22148909 [TBL] [Abstract][Full Text] [Related]
44. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia. Wallace SL; St Martin B; Lee K; Sokol ER Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659 [TBL] [Abstract][Full Text] [Related]
45. Clinical practice. Management of menopausal symptoms. Grady D N Engl J Med; 2006 Nov; 355(22):2338-47. PubMed ID: 17135587 [No Abstract] [Full Text] [Related]
46. Managing vasomotor symptoms in women after cancer. Pinkerton JV; Santen RJ Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391 [TBL] [Abstract][Full Text] [Related]
47. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Edwards D; Panay N Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589 [TBL] [Abstract][Full Text] [Related]
48. Prescribing hormone replacement therapy for menopausal symptoms. McNagny SE Ann Intern Med; 1999 Oct; 131(8):605-16. PubMed ID: 10523222 [TBL] [Abstract][Full Text] [Related]
49. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Al-Baghdadi O; Ewies AA Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185 [TBL] [Abstract][Full Text] [Related]
50. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. The NAMS 2020 GSM Position Statement Editorial Panel Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449 [TBL] [Abstract][Full Text] [Related]
51. Recommendations for the management of postmenopausal vaginal atrophy. Sturdee DW; Panay N; Climacteric; 2010 Dec; 13(6):509-22. PubMed ID: 20883118 [TBL] [Abstract][Full Text] [Related]
52. A Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms of Menopause. Fantasia HC Nurs Womens Health; 2016; 20(5):511-518. PubMed ID: 27719781 [TBL] [Abstract][Full Text] [Related]
54. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562 [TBL] [Abstract][Full Text] [Related]
55. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Potter N; Panay N Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054 [TBL] [Abstract][Full Text] [Related]
56. Alternatives for women through menopause. Gass ML; Taylor MB Am J Obstet Gynecol; 2001 Aug; 185(2 Suppl):S47-56. PubMed ID: 11521122 [TBL] [Abstract][Full Text] [Related]
57. [Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects]. Palácová M Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722 [TBL] [Abstract][Full Text] [Related]
58. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. Hickey M; Emery LI; Gregson J; Doherty DA; Saunders CM Menopause; 2010 Jul; 17(4):727-33. PubMed ID: 20512079 [TBL] [Abstract][Full Text] [Related]
59. Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. Sussman TA; Kruse ML; Thacker HL; Abraham J J Oncol Pract; 2019 Jul; 15(7):363-370. PubMed ID: 31291563 [TBL] [Abstract][Full Text] [Related]